Ignite Creation Date:
2024-05-05 @ 11:29 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01348347
Status:
COMPLETED
Last Update Posted:
2018-08-06
First Post:
2011-04-29
Brief Title:
BI 6727 Volasertib Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label phase I dose escalation trial 123015 is the first trial with Volasertib in Japanese advanced cancer patients The trial will investigate the maximum tolerated dose MTD safety tolerability and preliminary efficacy of this specific polo-like kinase 1 Plk1 inhibitor in advanced cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None